Recent Quotes (30 days)

You have no recent quotes
chg | %

Finance

Show: All - Companies - Funds
Results 1 - 28 of about 46 companies and 8 funds for growth factors
Company Exchange Symbol Last price Quote change Market cap
Novo Nordisk A/S (ADR) NYSE NVO 35.88 -0.52 (-1.43%) 71.45B
The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy.
Novo Nordisk A/S CPH NOVO-B 249.70 -2.70 (-1.07%) 502.54B
The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy.
Eli Lilly and Co NYSE LLY 81.89 -0.05 (-0.06%) 90.30B
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: ...
NOVO-NORDISK AS DKK0.2 SER'B' OTCMKTS NONOF 35.70 -0.74 (-2.02%) 73.33B
NOVO-NORDISK B ADR/1DK 10 FRA NOVA 33.86 -0.20 (-0.58%)
NOVO-NORDISK NAM.B DK-,20 ETR NOVC 33.58 -0.34 (-1.02%)
NOVO-NORDISK NAM.B DK-,20 FRA NOVC 33.68 -0.42 (-1.23%)
DAIICHI SANKYO COMPANY, LIMITED TYO 4568 2,441.00 +12.50 (0.51%) 1.73T
DAIICHI SANKYO COMPANY, LIMITED is a Japan-based holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is ...
NOVO-NORDISK B ADR/1DK 10 ETR NOVA 33.60 -0.32 (-0.94%)
Repligen Corporation NASDAQ RGEN 35.06 -0.78 (-2.18%) 1.16B
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to ...
China Pharma Holdings, Inc. NYSEMKT CPHI 0.250 -0.010 (-3.85%) 10.33M
China Pharma Holdings, Inc. is a holding company. The Company conducts its production, marketing, finance, development and administrative activities through ...
Antisense Therapeutics Limited ASX ANP 0.0330 0.0000 (0.00%) 5.83M
The Company's product candidate, ATL1103, is an antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the ...
Novo Nordisk SWX NOVOB 35.90 -0.34 (-0.94%)
Roche Holding AG ETR RHO5 106.90 -0.45 (-0.42%) 0.00
Roche Holding AG is a Switzerland-based pharmaceuticals and diagnostics company. It discovers, develops and provides diagnostic and therapeutic products ...
Five Prime Therapeutics Inc NASDAQ FPRX 32.99 +0.63 (1.95%) 967.51M
... in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, ...
ANTISENSE THERAPEUTI OTCMKTS ATHJY 0.0000 6.62M
ANTISENSE THERAPEU NPV OTCMKTS ATHJF 0.0350 0.0000 (0.00%) 6.18M
Helix Biopharma Corp. TSE HBP 0.980 -0.020 (-2.00%) 92.50M
... Phase I/II and Phase I clinical studies. V-DOS47 is an antibody DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor (VEGFR2) .
Hutchison China MediTech Limited LON HCM 2,999.14 -38.36 (-1.26%) 1.81B
Hutchison China MediTech Limited (Chi-Med) is a China-based, globally- focused healthcare group. The Company researches, develops, manufactures and ...
Loxo Oncology Inc NASDAQ LOXO 47.79 +1.08 (2.31%) 1.28B
Loxo Oncology, Inc. is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers.
Show all 46 companies »
Mutual Fund Symbol Nav Nav change
PNC Multi Factor Small Cap Growth Fund Class A PLWAX 22.20 -0.08 (-0.36%)
The investment seeks long-term capital appreciation. Under normal circumstances, the fund invests at least 80% of its net assets plus any borrowings for ...
Category:
Small Growth.
Gerstein Fisher Multi-Factor Growth Equity Fund GFMGX 19.39 -0.05 (-0.26%)
The investment seeks long-term capital appreciation. The fund invests at least 80 % of its net assets in equity securities. It invests primarily in common stocks of ...
Category:
Large Growth.
Gerstein Fisher Multi-Factor International Growth Equity Fund GFIGX 13.32 -0.04 (-0.30%)
The investment seeks long-term capital appreciation. Under normal market conditions, at least 80% of the fund's net assets will be invested in equity securities.
Category:
Foreign Large Growth.
PNC Multi-Factor Large Cap Growth Fund Class I PEWIX 31.40 -0.07 (-0.22%)
The investment seeks long-term capital appreciation. The fund primarily invests in a diversified portfolio of growth-oriented domestic equity securities of ...
Category:
Large Growth.
PNC Multi-Factor Large Cap Growth Fund Class A PEWAX 30.79 -0.07 (-0.23%)
The investment seeks long-term capital appreciation. The fund primarily invests in a diversified portfolio of growth-oriented domestic equity securities of ...
Category:
Large Growth.
PNC Multi Factor Small Cap Growth Fund Class I PLTIX 22.66 -0.08 (-0.35%)
The investment seeks long-term capital appreciation. Under normal circumstances, the fund invests at least 80% of its net assets plus any borrowings for ...
Category:
Small Growth.
PNC Multi-Factor Large Cap Growth Fund Class C PEWCX 27.95 -0.07 (-0.25%)
The investment seeks long-term capital appreciation. The fund primarily invests in a diversified portfolio of growth-oriented domestic equity securities of ...
Category:
Large Growth.
PNC Multi Factor Small Cap Growth Fund Class C PLWCX 21.52 -0.08 (-0.37%)
The investment seeks long-term capital appreciation. Under normal circumstances, the fund invests at least 80% of its net assets plus any borrowings for ...
Category:
Small Growth.